Ajanta Pharma Profile
Key Indicators
- Authorised Capital ₹ 30.00 Cr
- Paid Up Capital ₹ 25.18 Cr
- Company Age 45 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 65.00 Cr
- Satisfied Charges ₹ 548.84 Cr
- Revenue Growth 15.34%
- Profit Growth 44.48%
- Ebitda 60.08%
- Net Worth 5.15%
- Total Assets -2.03%
About Ajanta Pharma
Ajanta Pharma Limited (APL) is a leading Public Limited Indian Non-Government Company incorporated in India on 31 December 1979 and has a history of 45 years and one month. Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532331 and on the National Stock Exchange(NSE) under AJANTPHARM.
The Corporate was formerly known as Ajanta Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 30.00 Cr and a paid-up capital of Rs 25.18 Cr.
The company currently has active open charges totaling ₹65.00 Cr. The company has closed loans amounting to ₹548.84 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ajanta Pharma Limited India are Arvind Agrawal as CFO and Gaurang Shah as Company Secretary. Yogesh Agrawal, Mannalal Agrawal, Madhusudan Agrawal, and Five other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24230MH1979PLC022059
- Company No.
022059
- Stock Symbol
BSE : 532331 NSE : AJANTPHARM
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
31 Dec 1979
- Date of AGM
18 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Mumbai
Industry
What products or services does Ajanta Pharma Limited offer?
Ajanta Pharma Limited offers a wide range of products and services, including Skin Care, Bath Essentials, Women Care, Mother Care, Facewash, Hair Care, Hair Growth for Men, Ayurveda Products, Natural Hair & Skin Care, Hair Growth Supplements.
Who are the key members and board of directors at Ajanta Pharma?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Agrawal  | Managing Director | 29-Apr-2000 | Current |
| Arvind Agrawal | CFO | 30-Oct-2015 | Current |
| Gaurang Shah | Company Secretary | 08-Jan-2014 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajesh Dalal | Director | 29-May-2024 | Current |
| Mannalal Agrawal | Director | 31-Dec-1979 | Current |
| Madhusudan Agrawal | Whole-Time Director | 31-Dec-1979 | Current |
| Rajesh Agrawal | Whole-Time Director | 30-Apr-2013 | Current |
| Medha Joshi | Director | 29-May-2024 | Current |
| David Rasquinha | Director | 29-May-2024 | Current |
Financial Performance of Ajanta Pharma.
Ajanta Pharma Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 15.34% increase. The company also saw a substantial improvement in profitability, with a 44.48% increase in profit. The company's net worth moved up by a moderate rise of 5.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ajanta Pharma?
In 2024, Ajanta Pharma had a promoter holding of 66.22% and a public holding of 33.80%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Samta Mines And Minerals LimitedMadhusudan Agrawal is a mutual person
Ion Exchange (India) LimitedDavid Rasquinha is a mutual person
Inspira Realty & Infra Private LimitedMadhusudan Agrawal is a mutual person
Inspira Infra (Aurangabad) LimitedMadhusudan Agrawal is a mutual person
- Inspira Projects Limited
Madhusudan Agrawal is a mutual person
Lenexis Foodworks Private LimitedMadhusudan Agrawal is a mutual person
Charges (Loans)
₹65.00 Cr
₹548.84 Cr
Charges Breakdown by Lending Institutions
- Citi Bank N.A. : 35.00 Cr
- Others : 20.00 Cr
- Idbi Bank Limited : 10.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jan 2024 | Idbi Bank Limited | ₹10.00 Cr | Open |
| 11 Feb 2021 | Others | ₹10.00 Cr | Open |
| 26 Jun 2020 | Citi Bank N.A. | ₹35.00 Cr | Open |
| 03 Jul 1997 | Others | ₹10.00 Cr | Open |
| 21 Mar 2013 | State Bank Of Mauritius Limited | ₹55.16 Cr | Satisfied |
How Many Employees Work at Ajanta Pharma?
Ajanta Pharma has a workforce of 7869 employees as of Aug 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ajanta Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ajanta Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
